Research found physicians are frustrated with lack of effective current Txs for AML. Enthusiasm for enrolling patients in clinical trials, suggests physicians are keen to try new products and have little satisfaction with current ones.
If NI Tx is chosen the aim is not cure, the aim is for everyday QoL. This is the driving factor underlying Tx choices.
QoL is very personal, but key factors are: Staying away from hospital / reduced blood transfusions, minimal S/Es, dying in peace.
AML NI is a difficult and emotional treatment area for doctors to treat, due to: lack of Tx options, lack of confidence in outcomes for patients and terminally ill co-morbid patients with limited prospects. New products need to offer notable increases in OS with no worse / minimally worse S/Es. A new product will not have great traction if they have worse S/Es and little improvement in OS.
Proven clinical superiority over Decitabine monotherapy is essential, with tangible reductions in anaemia and associated health economic costs desirable.
Physician and patients work together on choosing Tx choice (DoH guidelines). All Tx choices are authorised by the Multi-Disciplinary Team so personal values of the physician do not necessarily impact Tx choice. Treating AML is personal. No magic bullet. No cookie cutter treatment approach.
Purpose, to understand treatment landscape for Clostridium difficile infections (CDI) and the key challenges to be addressed and a product profile review.